We won’t need to fully treat 250 patients to know
After the first few patients receive ciab and ifosfamide we’ll know if the technology shrinks the tumors.
We can afford to treat say thirty patients without needing the full funds a phase 2b would visit.
Early results should be good because of improvements to encapsulation, more activating cells per cap and better imaging. Add in multi doses and we’ll quickly know if this works in a few weeks after it’s first applications.
Then there will be a rush to get patients to enroll on a side effects free tumor busting technology like ours and quite likely even breakthrough from the fda due to its life saving results.
Then consider it being used with immunotherapy. Chemo and immunotherapy doubled life expectancy in the recent Merck lung cancer trials. Imagine immunotherapy and ‘targeted’ chemo and no side effects.
We don’t need a huge amount of money or a major partner to get those first results. And they will change everything.
What we need is a successful ind, expertly and perfectly submitted to avoid doubts and delays and the first results from human patients with inoperable pc.
Exciting... for patients and for all of us.
After first results are announced there will be no way you can buy pcmb for 5cents a share.
A targeted side effect free chemo that partners perfectly with opdivo or keytruda.
Priceless.
Once we have those first tumor shrinking results and a large number of inoperable tumors become operable for this unmet medical need, can anyone guess how much the wealthy pancreatic cancer foundations will offer to fund something like this? With Hidalgo, Lohr and Von HOFF involved?
News 
Market Data 
Discover 
